As of August 29, 2026, Gyre Therapeutics's top three insider holders are Ying Luo (Director, 2.84Mn shares), Songjiang Ma (President, 2.81Mn shares), Songjiang Ma (President, 2.81Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Songjiang Ma | President | 0 | 2,806,084 | 2,806,084 | 45.0% | 29 May, 2025 |
| 2 | Ying Luo | Chief Executive Officer | 0 | 2,565,226 | 2,565,226 | 41.2% | 07 May, 2026 |
| 3 | Weiguo Ye | Chief Operating Officer | 700,000 | 0 | 700,000 | 11.2% | 15 Jun, 2026 |
| 4 | Group Ltd. Gni | TenPercentOwner | 0 | 40,644 | 40,644 | 0.7% | 22 Nov, 2023 |
| 5 | Eddie Williams | Director | 34,804 | 0 | 34,804 | 0.6% | 07 Jan, 2022 |
| 6 | Geoffrey M.D. Ling | Director | 31,790 | 0 | 31,790 | 0.5% | 07 Jan, 2022 |
| 7 | Andrea Hunt | Director | 28,228 | 0 | 28,228 | 0.5% | 07 Jan, 2022 |
| 8 | Thomas Wilson Eastling | Director | 15,000 | 0 | 15,000 | 0.2% | 18 Apr, 2025 |
| 9 | Seline E. Miller | Svp Finance; Interim Cfo Pao | 6,500 | 0 | 6,500 | 0.1% | 10 Aug, 2022 |
| 10 | Nassim Usman | President Ceo | 1,636 | 0 | 1,636 | 0.0% | 01 Jul, 2024 |
| 11 | Howard Levy | Chief Medical Officer | 639 | 0 | 639 | 0.0% | 11 Aug, 2021 |
| 12 | Errol B Desouza | Director | 19 | 0 | 19 | 0.0% | 05 Oct, 2021 |
| 13 | Grant E. Blouse | Chief Scientific Officer | 6 | 0 | 6 | 0.0% | 10 Aug, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 03 Aug, 2026 | Claire Weston | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 03 Aug, 2026 | Maxwell Kirkby | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 10 Jun, 2026 | Renate Parry | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 10 Jun, 2026 | Rodney L Nussbaum | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 10 Jun, 2026 | Gordon Carmichael | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 10 Jun, 2026 | Dan Weng | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 10 Jun, 2026 | David M. Epstein | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 10 Jun, 2026 | Ping Zhang | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 09 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Acquired M | 3,000 | $0.75 | $2.25K | 703,000 | Direct |
| 09 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed S | 3,000 | $6.15 | $18.45K | 700,000 | Direct |
| 10 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Acquired M | 5,000 | $0.75 | $3.75K | 705,000 | Direct |
| 10 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed S | 5,000 | $6.24 | $31.20K | 700,000 | Direct |
| 18 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Acquired M | 3,000 | $0.75 | $2.25K | 703,000 | Direct |
| 18 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed S | 3,000 | $6.35 | $19.05K | 700,000 | Direct |
| 09 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed M | 3,000 | $0.00 | $0 | 835,701 | Direct |
| 10 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed M | 5,000 | $0.00 | $0 | 830,701 | Direct |
| 18 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed M | 3,000 | $0.00 | $0 | 827,701 | Direct |
| 11 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Acquired M | 2,800 | $0.75 | $2.10K | 702,800 | Direct |
| 11 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed S | 2,800 | $6.17 | $17.28K | 700,000 | Direct |
| 11 Jun, 2026 | Weiguo Ye | Chief Operating Officer | Disposed M | 2,800 | $0.00 | $0 | 838,701 | Direct |